506128 Stock Overview
Parnax Lab Limited manufactures and sells pharmaceutical formulations in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Parnax Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹114.50 |
| 52 Week High | ₹167.90 |
| 52 Week Low | ₹55.00 |
| Beta | 0.77 |
| 1 Month Change | -20.26% |
| 3 Month Change | 34.15% |
| 1 Year Change | 59.60% |
| 3 Year Change | 354.37% |
| 5 Year Change | 292.12% |
| Change since IPO | 1,263.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506128 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.8% | -3.4% | -3.7% |
| 1Y | 59.6% | 53.6% | 38.4% |
Return vs Industry: 506128 exceeded the Indian Pharmaceuticals industry which returned 53.6% over the past year.
Return vs Market: 506128 exceeded the Indian Market which returned 38.4% over the past year.
Price Volatility
| 506128 volatility | |
|---|---|
| 506128 Average Weekly Movement | 11.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 506128's share price has been volatile over the past 3 months.
Volatility Over Time: 506128's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 12 | Prakash Shah | www.naxparlab.com |
Parnax Lab Limited manufactures and sells pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; and medicinal products. It provides cosmetic products; herbal; and nutraceutical products.
Parnax Lab Limited Fundamentals Summary
| 506128 fundamental statistics | |
|---|---|
| Market cap | ₹1.33b |
| Earnings (TTM) | ₹88.07m |
| Revenue (TTM) | ₹1.83b |
14.9x
P/E Ratio0.7x
P/S RatioIs 506128 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506128 income statement (TTM) | |
|---|---|
| Revenue | ₹1.83b |
| Cost of Revenue | ₹1.05b |
| Gross Profit | ₹778.70m |
| Other Expenses | ₹690.63m |
| Earnings | ₹88.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.67 |
| Gross Margin | 42.49% |
| Net Profit Margin | 4.81% |
| Debt/Equity Ratio | 87.5% |
How did 506128 perform over the long term?
See historical performance and comparison